Transmedics Group Stock Price, News & Analysis

TransMedics Group, Inc. (TMDX) reported a 125% increase in net revenue for Q1 2022, reaching $15.9 million, up from $7.1 million in Q1 2021. The company received FDA pre-market approval for OCS™ DCD heart indication and presented significant clinical trial data at ISHLT 2022. However, operating expenses rose to $21.5 million from $11.3 million, leading to a net loss of $10.6 million. The full-year revenue guidance was updated to $59 million to $65 million, reflecting a growth of 95% to 115%.

TransMedics Group announced on April 28, 2022, that the FDA granted premarket approval for its OCS™ Heart System to be used with donor hearts after circulatory death (DCD). This crucial approval expands the donor heart pool in the U.S., complementing the prior approval for brain death donors received in September 2021. The OCS™ Heart System facilitates ex vivo reanimation and functional monitoring of DCD hearts. CEO Waleed Hassanein emphasized the milestone's potential to enhance patient access to heart transplants. Final results from the OCS™ DCD Heart Trial will be presented on April 29, 2022.

TransMedics Group, Inc. (TMDX) announced on April 18, 2022, the grant of non-qualified stock options to three employees, allowing the purchase of 29,800 shares of common stock at an exercise price of $22.48. The stock options were approved by the Compensation Committee and adhere to Nasdaq Listing Rule 5635(c)(4). Vesting includes a 25% share after the first year and the remainder monthly over three years, contingent on continued employment. TransMedics focuses on organ transplant therapy innovation, enhancing organ viability and utilization for patients with end-stage organ failure.

TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will announce its first-quarter 2022 financial results on May 3, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Investors can access the call by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using Conference ID: 215877. The company aims to enhance organ preservation and assessment for transplants, addressing vital needs in heart, lung, and liver failure treatments.

TransMedics Group announces the presentation of new clinical data from its OCS™ Heart and Lung trials at the ISHLT 2022 Annual Meeting, scheduled for April 27-30, 2022, in Boston, MA. Key presentations include long-term results from the OCS DCD Heart trial and the OCS Lung EXPAND trial. These findings may significantly impact organ transplant therapy for patients with end-stage organ failure. TransMedics is set to host a symposium featuring global transplant leaders discussing their experiences with the OCS technology.

TransMedics Group, Inc. (Nasdaq: TMDX) will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 p.m. EST. The company is at the forefront of improving organ transplant therapy for patients with end-stage heart, lung, and liver failure. A live and archived webcast of the presentation will be available on their Investors section. TransMedics specializes in portable extracorporeal warm perfusion and assessment of donor organs, enhancing organ viability and increasing usage rates.

TransMedics Group, Inc. (TMDX) announced on February 22, 2022, that it granted non-qualified stock options for 158,500 shares to eight new employees as an inducement to join the company. These options have an exercise price of $13.28, matching the Nasdaq closing price on the grant date. The options will vest 25% after one year, with the remainder vesting monthly over the next three years. The move aims to enhance employee retention as part of the company's growth strategy in organ transplant therapy, focusing on better organ quality and utilization.

TransMedics Group, Inc. (TMDX) reported strong financial results for 2021. Net revenue reached $9.7 million in Q4 2021, up 27% year-over-year. Full-year revenue increased 18% to $30.3 million. The company launched OCS™ Heart and OCS™ Liver in the U.S., significantly contributing to revenue growth. However, net loss widened to $12.7 million for Q4 and $44.2 million for the year. The gross margin improved to 72% in Q4 and 70% for the year. For 2022, TransMedics projects revenue between $49 million and $55 million, indicating potential growth of 62% to 82%.

TransMedics Group (Nasdaq: TMDX) will present at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:50 a.m. EST. The executive team's presentation aims to highlight advancements in organ transplant therapy, particularly for patients experiencing end-stage lung, heart, and liver failure. TransMedics is a leader in portable warm perfusion technology, focusing on improving organ quality and viability assessment prior to transplantation.

Investors can access a live and archived webcast of the presentation on the TransMedics website.